Haloperidol and atypical antipsychotics share a same action of decreasing P75NTR mRNA levels in PC12 cells

Life Sciences

Volumn 79, Issue 6, 2006, Pages 570-574

  Bai, Ou ^a,b   Xu, Haiyun ^a   Li, Xin Min ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b JILIN UNIVERSITY   (China)

Author keywords

Antipsychotics; Cell culture; p75NTR; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; NEUROTROPHIN RECEPTOR; PROTEIN P75; QUETIAPINE; RISPERIDONE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL STRAIN; CELL VIABILITY; CHRONOPHARMACOLOGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; GENE CONTROL; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; RECEPTOR DOWN REGULATION; RNA ANALYSIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL SURVIVAL; CLOZAPINE; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION; HALOPERIDOL; PC12 CELLS; RATS; RECEPTOR, NERVE GROWTH FACTOR; RISPERIDONE; RNA, MESSENGER; TIME FACTORS;

EID: 33745197124     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.01.039     Document Type: Article

References (44)

1. Angelucci F., Aloe L., Iannitelli A., Gruber S.H.M., and Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. European Neuropsychopharmacology 15 (2005) 311-317
2. Ardizzone T.D., Bradley R.J., Freeman A.M., and Dwyer D.S. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Research 923 (2001) 82-90
3. Bai O., Wei Z., Lu W., Bowen R., Keegan D., and Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. Journal of Neuroscience Research 69 (2002) 278-283
4. Bai O., Chlan-Fourney J., Bowen R., Keegan D., and Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research 71 (2003) 127-131
5. Bersani G., Iannitelli A., Maselli P., Pancheri P., Aloe L., Angelucci F., and Alleva E. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophrenia Research 37 (1999) 201-203
6. Bilder R.M. Neurocognitive impairment in schizophrenia and how it affects treatment options. Canadian Journal of Psychiatry 42 (1997) 255-264
7. Bredesen D.E., and Rabizadeh S. p75NTR and apoptosis: Trk-dependent and Trk-independent effects. Trends in Neuroscience 20 (1997) 287-290
8. Breier A., Buchanan R.W., Waltrip R.W., Listwak S., Holmes C., and Goldstein D.S. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 10 (1994) 1-7
9. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., and Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 16 (1990) 551-561
10. Chao M.V. Neurotrophins and their receptors: a convergence point for many signaling pathways. Nature Reviews. Neuroscience 4 (2003) 299-309
11. Chatterjee A., Chakos M., Koreen A., Geisler S., Sheitman B., Woerner M., Kane J.M., Alvir J., and Lieberman J.A. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. American Journal of Psychiatry 152 (1995) 1724-1729
12. Chlan-Fourney J., Ashe P., Nylen K., Juorio A.V., and Li X.M. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Research 954 (2002) 11-20
13. Cosi C., Waget A., Rollet K., Tesori V., and Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Research 1043 (2005) 32-41
14. DeLisi L.E. Is schizophrenia a lifetime disorder of brain plasticity, growth and aging?. Schizophrenia Research 23 (1997) 119-129
15. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., and Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophrenia Research 52 (2001) 79-86
16. Dwyer D.S., Liu Y., and Bradley R.J. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neuroscience Letters 274 (1999) 151-154
17. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. Journal of Psychiatry Research 17 (1982) 319-334
18. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
19. Gentry J.J., Barker P.A., and Carter B.D. The p75 neurotrophin receptor: multiple interactors and numerous functions. Progress in Brain Research 146 (2004) 25-39
20. He J., Yang Y., Xu H., Zhang X., and Li X.M. Olanzapine attenuates the okadaic acid induced spatial memory impairment and hippocampal cell death in rats. Neuropsychopharmacology 30 (2005) 1511-1520
21. Huang E.J., and Reichardt L.F. Trk receptors: roles in neuronal signal transduction. Annual Review of Biochemistry 72 (2001) 609-642
22. Jibson M.D., and Tandon R. New atypical antipsychotic medications. Journal of Psychiatry Research 32 (1998) 215-228
23. Lewis D.A., and Levitt P. Schizophrenia as a disorder of neurodevelopment. Annual Review of Neuroscience 25 (2002) 409-432
24. Li X.M., Chlan-Fourney J., Juorio A.V., Bennett V.L., Shrikhande S., Keegan D.L., Qi J., and Boulton A.A. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. Journal of Neuroscience Research 56 (1999) 72-75
25. Lindenmayer J.P. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatrica Scandinavica. Supplementum 388 (1995) 15-19
26. Lu X.H., and Dwyer D.S. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. Journal of Molecular Neuroscience 27 (2005) 43-64
27. Lu X.H., Bradley R.J., and Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Research 1011 (2004) 58-68
28. Mehlen P., and Bredesen D.E. The dependence receptor hypothesis. Apoptosis 9 (2004) 37-49
29. Meltzer H.Y., Lee M.A., and Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatrica Scandinavica. Supplementum 384 (1994) 95-101
30. Miyamoto S., LaMantia A.S., Duncan G.E., Sullivan P., Gilmore J.H., and Lieberman J.A. Recent advances in the neurobiology of schizophrenia. Molecular Interventions 3 (2003) 27-39
31. Nykjaer A., Willnow T.E., and Petersen C.M. P75NTR-live or let die. Current Opinion in Neurobiology 15 (2005) 49-57
32. Parikh V., Evans D.R., Khan M.M., and Mahadik S.P. Nerve growth factor in never medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophrenia Research 60 (2003) 117-123
33. Parikh V., Khan M.M., and Mahadik S.P. Olanzapine counteracts reduction of brain derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neuroscience Letters 356 (2004) 135-139
34. Parikh V., Terry A.V., Khan M.M., and Mahadik S.P. Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology 172 (2004) 365-374
35. Pirildar S., Gonul A.S., Taneli F., and Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Progress in Neuro-psychopharmacol & Biological Psychiatry 28 (2004) 709-713
36. Qing H., Xu H., Wei Z., Gibson K., and Li X.M. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. European Journal of Neuroscience 17 (2003) 1563-1570
37. Rabizadeh S., and Bredesen D.E. Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). Cytokine and Growth Factor Reviews 14 (2003) 225-239
38. Roux P.P., and Barker P.A. Neurotrophin signaling through the p75 neurotrophin receptor. Progress in Neurobiology 67 (2002) 203-233
39. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., and Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Research 110 (2002) 249-257
40. Wang H., Xu H., Dyck L.E., and Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. Journal of Neuroscience Research 81 (2005) 572-580
41. Wei Z., Bai O., Richardson J.S., Mousseau D.D., and Li X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. Journal of Neuroscience Research 73 (2003) 364-368
42. Wei Z., Mousseau D.D., Richardson J.S., Dyck L.E., and Li X.M. Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. Journal of Neuroscience Research 74 (2003) 942-947
43. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., and Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Molecular Psychiatry 8 (2003) 592-610
44. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 44 (1987) 660-669